Coherus Oncology Inc CHRS

US Biotechnology

$0.63 ▼ -23.51% ($-0.19)

🧊 52W Low ⬇️ Below Yest. Low

Open $0.80

Prev Close $0.82

Day Range $0.62 – $0.80

52W Range $0.73 – $2.62

Market Cap $126.32M

P/E (TTM) 0.75

Beta 1.08

EPS (TTM) $-1.03

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2014-11-06
Shares Out.	154,500,000
Website	coherus.com ↗
Phone	13026587581
Employees	144
Revenue	$14.3M
Gross Profit	$10.1M
Net Income	-$20.6M
Free Cash Flow	-$664.7M
Total Assets	$191.2M
Total Liabilities	$130.3M
Equity	$60.8M

About Coherus Oncology Inc

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Coherus Oncology Inc is a publicly traded company under the ticker symbol CHRS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.